Project Grant R01AI189600
Award Date 9/10/25
Completion Date 8/31/28
Dollars Obligated $549K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $813,160 to George Washington University to develop mRNA-LNP combination vaccines targeting multiple stages and species of the human malaria parasite. The grant aims to evaluate the protective efficacy of various vaccine antigens, including PFS25, PFS230, PFCSP, PVS25, and a chimeric PVCSP, both individually...
- This $122,597 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to analyze the function and antibody-mediated inhibition of the malaria vaccine candidate protein PF3D7_1136200. The project aims to characterize this promising but previously uncharacterized blood-stage malaria antigen, with the goal of advancing development of a highly efficacious malaria vaccine. The...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $375,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of South Florida (USF) to study the functions of messenger ribonucleoprotein (mRNP) granules in regulating mRNA metabolism in the malaria parasite Plasmodium falciparum. The project, running from Jun 10, 2025 to May 31, 2030, aims to identify mRNP markers, characterize their protein and mRNA compositions, and...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $682,200 Project Grant to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) on August 22, 2025. The grant will support a study to evaluate the impact of early-life malaria exposure on the effectiveness of the RTS,S pre-erythrocytic malaria vaccine in Kenyan infants. The study aims to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $406,450 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Harvard T.H. Chan School of Public Health. The grant supports research to develop a continuous in vitro culture system for the Plasmodium vivax malaria parasite. Key objectives include optimizing the production of host reticulocytes (young red blood cells) to support P. vivax growth, iteratively improving culture conditions...
- The University of South Florida received a $412,500 project grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to evaluate immunodominant fragments of the PfGARP protein as a potential malaria vaccine candidate. The project aims to identify critical immunogenic regions within PfGARP that can generate functional antibodies and growth inhibition activity comparable to the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $807,330 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research focused on improving antibody-based protection against Plasmodium falciparum (P. falciparum) and Plasmodium vivax (P. vivax) malaria. The project aims to identify new antibody variants with at least...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $107,542 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in Missouri. The grant, effective September 1, 2025 through August 31, 2027, aims to unravel the mechanisms underlying the differential sorting and trafficking of Plasmodium falciparum secreted proteins during the symptomatic stage of malaria. The research seeks to determine how exported proteins...
- The University of Washington received a $310,492 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to conduct research on understanding and overcoming Plasmodium-specific immune evasion mechanisms. The research aims to examine how Plasmodium infection influences the pre-vaccine circumsporozoite protein (CSP)-specific memory B cell pool, in order to identify why current malaria vaccines are ineffective in...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) will support research to define the immune response to Plasmodium vaccination and test an adjuvant to boost immunity against malaria. The $205,125 award to the Hennepin Healthcare Research Institute will utilize an improved small animal model to compare vaccine responses in specific pathogen-free (SPF) mice versus...